{
    "xml": "<topic id=\"PHP79663\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/modigraf\" basename=\"modigraf\" title=\"Modigraf\">\n<title>Modigraf<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP79716\" outputclass=\"indicationsAndDose\" rev=\"1.34\" parent=\"/clinical-medicinal-product-information/modigraf\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8211;200&#8239;micrograms/kg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 200&#8211;300&#8239;micrograms/kg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 75&#8239;micrograms/kg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 75&#8239;micrograms/kg daily in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Rejection therapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Seek specialist advice.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP79816\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/modigraf\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (November 2010) that tacrolimus granules for oral suspension (<i>Modigraf</i>\n<tm tmtype=\"reg\"/>) are accepted for restricted use within NHS Scotland in patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy and where small changes (less than 500&#8239;micrograms) in dosing increments are required (such as, in paediatric patients) or seriously ill patients who are unable to swallow tacrolimus capsules.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP79663",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/modigraf",
    "basename": "modigraf",
    "title": "Modigraf",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation",
                        "html": "Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 100&#8211;200 micrograms/kg daily in 2 divided doses.",
                        "html": "<p>Initially 100&#8211;200&#8239;micrograms/kg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation",
                        "html": "Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 200&#8211;300 micrograms/kg daily in 2 divided doses.",
                        "html": "<p>Initially 200&#8211;300&#8239;micrograms/kg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation",
                        "html": "Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 75 micrograms/kg daily in 2 divided doses.",
                        "html": "<p>Initially 75&#8239;micrograms/kg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation",
                        "html": "Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 75 micrograms/kg daily in 2 divided doses.",
                        "html": "<p>Initially 75&#8239;micrograms/kg daily in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Rejection therapy",
                        "html": "Rejection therapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Seek specialist advice.",
                        "html": "<p>Seek specialist advice.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (November 2010) that tacrolimus granules for oral suspension (Modigraf ) are accepted for restricted use within NHS Scotland in patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy and where small changes (less than 500 micrograms) in dosing increments are required (such as, in paediatric patients) or seriously ill patients who are unable to swallow tacrolimus capsules.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (November 2010) that tacrolimus granules for oral suspension (<i>Modigraf</i> <tm tmtype=\"reg\"/>) are accepted for restricted use within NHS Scotland in patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy and where small changes (less than 500&#8239;micrograms) in dosing increments are required (such as, in paediatric patients) or seriously ill patients who are unable to swallow tacrolimus capsules.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}